Status:

RECRUITING

Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome

Lead Sponsor:

Peking Union Medical College Hospital

Conditions:

Polycystic Ovary Syndrome

Eligibility:

All Genders

18-45 years

Phase:

NA

Brief Summary

This study prospectively includes PCOS patients with normal weight and overweight/obesity, closely follows up and intensively manages them, and observes the level and distribution of weight reduction ...

Detailed Description

This study is a single-center, prospective cohort study that enrolled PCOS patients after screening. The patients were categorized into two groups based on their BMI: a normal weight group (18.5 kg/m2...

Eligibility Criteria

Inclusion

  • Women aged 18-45 years in the reproductive period;
  • Women who have previously met the Rotterdam diagnostic criteria (at least 2 of the following 3 criteria have been confirmed, and have been diagnosed with PCOS): 1) Oligomenorrhea and/or anovulation; 2) clinical and/or biochemical evidence of hyperandrogenism; 3) ultrasound showing the presence of unilateral or bilateral polycystic ovaries;
  • Inclusion of 50 women in the normal weight group: 18.5 kg/m² ≤ BMI \< 24 kg/m²; Inclusion of 400 women in the overweight/obese group: BMI ≥ 24 kg/m²;
  • Voluntarily participate in the intervention and sign an informed consent form.

Exclusion

  • Currently pregnant or lactating, or have had a recent (within 6 months) plan for pregnancy;
  • Currently using known prescription weight loss medications (such as GLP-1RA, orlistat, topiramate, etc.);
  • History of weight loss surgery;
  • History of severe cardiovascular or cerebrovascular diseases; severe liver or kidney dysfunction (ALT \> 3 times the upper limit of normal, or creatinine \> 1.5 times the upper limit of normal); chronic or active gastrointestinal inflammatory diseases; severe systemic diseases; active malignant tumors;
  • Secondary obesity: including hypothalamic or pituitary obesity, obesity secondary to glucocorticoid use, hypogonadism-induced obesity, etc.;
  • Known history of serious endocrine system diseases;
  • Poor compliance with planned dietary interventions (psychiatric disorders such as binge eating disorder, anorexia nervosa, severe anxiety/depression);
  • Unable to follow up on time or deemed non-cooperative by the investigator.

Key Trial Info

Start Date :

August 13 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2026

Estimated Enrollment :

425 Patients enrolled

Trial Details

Trial ID

NCT06545721

Start Date

August 13 2024

End Date

April 1 2026

Last Update

December 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730